Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma

Within the past year, several publications have compared the outcomes of clinical trials in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or R/R multiple myeloma (MM) against retrospective real-world datasets.1-4 Two such datasets include the SCHOLAR-1 cohort in DLBCL (comprising 636 patients analysed between 2001 and 2014) and the MAMMOTH cohort in MM (comprising 275 patients analysed between 2017 and 2018).5, 6 When these...